Micro-cap opioid biotech Avenue Therapeutics prices IPO at $6, midpoint of the lowered range – Nasdaq

Micro-cap opioid biotech Avenue Therapeutics prices IPO at $6, midpoint of the lowered rangeNasdaqAvenue Therapeutics, which is a Fortress Biotech spinoff developing an IV formulation of the opioid tramadol, raised $33 million by offering 5.5 million shares at $6, the midpoint of the $5 to $7 lowered range. Avenue Therapeutics plans to list on the […]

from WordPress http://ift.tt/2tgTsn9
via IFTTT

Newer Post Older Post